Intelligence Β· Clinical Pipeline
Teva Pharma Pipeline
All ClinicalTrials.gov programs at Teva Pharma β phase, modality, and trial IDs.
- Programs
- 126
Quick answer
Teva Pharma has 126 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Glatiramer Acetate, N-Acetylcysteine
Teva Pharma GmbH
Relapse Remitting Multiple Sclerosis
1 trial -
Homoharringtonine
Teva Pharma GmbH
Myeloid Leukemia, Chronic
1 trial -
Hydroxychloroquine (HCQ)
Teva Pharma GmbH
COVID-19
1 trial -
LBR-101 High Dose
Teva Pharma GmbH
Episodic Migraine Headache
1 trial -
LBR-101 High Dose
Teva Pharma GmbH
Chronic Migraine
1 trial -
Laquinimod
Teva Pharma GmbH
Huntington's Disease
1 trial -
Laquinimod
Teva Pharma GmbH
Lupus Nephritis
1 trial -
Laquinimod
Teva Pharma GmbH
Lupus Arthritis
1 trial -
Laquinimod
Teva Pharma GmbH
Crohn's Disease
1 trial -
Laquinimod 0.6
Teva Pharma GmbH
Relapsing Multiple Sclerosis
1 trial -
Larazotide Acetate
Teva Pharma GmbH
Celiac Disease
1 trial -
Liposomal doxorubicin hydrochloride
Teva Pharma GmbH
Breast Cancer
1 trial -
Metronidazole
Teva Pharma GmbH
Bacterial Vaginosis
1 trial -
Modakafusp Alfa
Teva Pharma GmbH
Neoplasms
1 trial -
Modakafusp alfa
Teva Pharma GmbH
Multiple Myeloma
3 trials -
Mometasone furoate
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
Nebulized IVX-0142
Teva Pharma GmbH
Asthma
1 trial -
Obatoclax
Teva Pharma GmbH
Extensive-stage Small Cell Lung Cancer
1 trial -
Obatoclax
Teva Pharma GmbH
AML
1 trial -
Obatoclax Mesylate
Teva Pharma GmbH
Metastatic Melanoma
1 trial -
Obatoclax mesylate
Teva Pharma GmbH
Mantle-Cell Lymphoma
1 trial -
Obatoclax mesylate
Teva Pharma GmbH
Lymphoma, Follicular
1 trial -
Obatoclax mesylate (GX15-070MS)
Teva Pharma GmbH
Myelodysplastic Syndromes
1 trial -
Obatoclax mesylate (GX15-070MS)
Teva Pharma GmbH
Hodgkin's Lymphoma
1 trial -
Obatoclax mesylate (GX15-070MS)
Teva Pharma GmbH
Myelofibrosis
1 trial -
Obatoclax mesylate 250 ml
Teva Pharma GmbH
Lung Cancer
1 trial -
Omacetaxine
Teva Pharma GmbH
Myelodysplastic Syndromes
1 trial -
Omacetaxine
Teva Pharma GmbH
Acute Myelogenous Leukemia (AML)
1 trial -
Omacetaxine
Teva Pharma GmbH
Leukemia
2 trials -
Omacetaxine mepesuccinate
Teva Pharma GmbH
Chronic Myeloid Leukemia
3 trials -
Oral CEP-701
Teva Pharma GmbH
Myeloma
1 trial -
Placebo
Teva Pharma GmbH
Primary Progressive Multiple Sclerosis
1 trial -
Rasagiline
Teva Pharma GmbH
Dementia
1 trial -
Reslizumab
Teva Pharma GmbH
Severe Asthma
1 trial -
SDX-101 (R-Etodolac)
Teva Pharma GmbH
Multiple Myeloma
1 trial -
SDX-105
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
TEV-45478
Teva Pharma GmbH
Nonalcoholic Steatohepatitis
1 trial -
TEV-48574
Teva Pharma GmbH
Crohn Disease
1 trial -
TEV-48574
Teva Pharma GmbH
Asthma
1 trial -
TEV-48574 Dose Regimen A
Teva Pharma GmbH
Crohn Disease
1 trial -
TEV-53275 Dose A
Teva Pharma GmbH
Asthma
1 trial -
TEV-53408
Teva Pharma GmbH
Celiac Disease
1 trial -
TEV-56286
Teva Pharma GmbH
Multiple System Atrophy
2 trials -
TP-38
Teva Pharma GmbH
Glioblastoma Multiforme
1 trial -
TP-38
Teva Pharma GmbH
Recurrent Glioblastoma Multiforme
1 trial -
TV-1380 150 mg
Teva Pharma GmbH
Cocaine Addiction
1 trial -
TV-45070
Teva Pharma GmbH
Postherpetic Neuralgia
1 trial -
TV-45070
Teva Pharma GmbH
Osteoarthritis of the Knee
1 trial
Frequently asked questions
How many pipeline programs does Teva Pharma have?
126 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources Β· All pipeline programs